Φορτώνει......

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

PURPOSE: CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers a synergistic 5:1 drug ratio into leukemia cells to a greater extent than normal bone marrow cells. Prior clinical studies demonstrated a sustained drug ratio and exposure in vivo and prolonged survi...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:J Clin Oncol
Κύριοι συγγραφείς: Lancet, Jeffrey E., Uy, Geoffrey L., Cortes, Jorge E., Newell, Laura F., Lin, Tara L., Ritchie, Ellen K., Stuart, Robert K., Strickland, Stephen A., Hogge, Donna, Solomon, Scott R., Stone, Richard M., Bixby, Dale L., Kolitz, Jonathan E., Schiller, Gary J., Wieduwilt, Matthew J., Ryan, Daniel H., Hoering, Antje, Banerjee, Kamalika, Chiarella, Michael, Louie, Arthur C., Medeiros, Bruno C.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society of Clinical Oncology 2018
Θέματα:
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6127025/
https://ncbi.nlm.nih.gov/pubmed/30024784
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.77.6112
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!